Systematic Reviews
Copyright ©The Author(s) 2022.
World J Clin Oncol. Oct 24, 2022; 13(10): 822-834
Published online Oct 24, 2022. doi: 10.5306/wjco.v13.i10.822
Table 4 Patient demographics, NLR cut-off value, follow up and time of sample acquisition for patients treated with radio-frequency ablation, radioembolization or solely chemotherapy
Ref.
Number of patients and procedure
Sex
Mean age (yr)
NLR threshold
Follow up (mo)
Sample acquisition
Tohme et al[29]104 RE69 M, 35 F60.8 ± 12.2, NLR > 5, 66.4 ± 12.2, NLR < 55100 patients died during follow upSame day before RE
Chang et al[26]98 RFA56 M, 42 F62 (28-92)2.535.2 ± 21.891 d before RFA - 1 mo after RFA
Zhang et al[27]92 RFA51 M, 41 F59 (43-78)527.1 ± 9.8 (range 5-62)Preoperatively as part of the routine workup. 1-3 d before RFA
Weiner et al[28]131 RE84 M, 47 F595117 deaths during follow upNS
Kishi et al[15]90 chemotherapy61 M, 29 F56528 (2-102)
Wu et al[31]55 chemotherapy35 M, 20 F594Complete clinical records (no exact mention)Preoperatively and before 2nd cycle of chemotherapy
Philips et al[30]71--5--